APA (7th ed.) Citation

Holch, J., Ricard, I., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., . . . Heinemann, V. (2019). Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). European Journal of Cancer, 106, 115. https://doi.org/10.1016/j.ejca.2018.10.001

Chicago Style (17th ed.) Citation

Holch, J.W, et al. "Relevance of Baseline Carcinoembryonic Antigen for First-line Treatment Against Metastatic Colorectal Cancer with FOLFIRI Plus Cetuximab or Bevacizumab (FIRE-3 Trial)." European Journal of Cancer 106 (2019): 115. https://doi.org/10.1016/j.ejca.2018.10.001.

MLA (9th ed.) Citation

Holch, J.W, et al. "Relevance of Baseline Carcinoembryonic Antigen for First-line Treatment Against Metastatic Colorectal Cancer with FOLFIRI Plus Cetuximab or Bevacizumab (FIRE-3 Trial)." European Journal of Cancer, vol. 106, 2019, p. 115, https://doi.org/10.1016/j.ejca.2018.10.001.